Peer-Reviewed Publications

UCB believes that publishing research results in scientific peer-reviewed journals puts data in context, avoids publication bias, and is beneficial to the scientific community, researchers, and ultimately benefits patients. Peer-review is an editorial process where independent scientific experts review the research for robustness and scientific value before being published.

UCB is committed to submitting the results of all clinical studies for publication, regardless of whether the results are positive or negative. UCB submits the information to journals that are specialized, which means the journals focus on specific health topics or types of disease.

Since 2014, UCB has adhered to the standards set out by the European Federation of Pharmaceutical Industries and Associations & Pharmaceutical Research and Manufacturers of America Principles for Responsible Clinical Trial Data Sharing, followed established guidelines in medical and scientific publishing including the International Committee of Medical Journal Editors Recommendations and Good Publication Practice 3.

UCB’s Policy for Peer-Reviewed Publications is:

Studies that begin after 16 March 2026

UCB will aim to publish all company-sponsored Phase 2-4 clinical trials in peer-reviewed journals, regardless of the results, unless there is a significant reason why publication is not feasible or not advisable. This will also include clinical-trial data from investigational medicinal products whose development programs have been discontinued.

document_icon_light_blue_200x200.png

Studies that begin after 31 March 2020

UCB will strive to submit for publication results from all “in-scope RWE studies” [1]  within 18 months after study completion. 

stopwatch_icon_light_blue_S.png

UCB strives to submit the results of UCB-sponsored clinical studies in Phase 2-4, regardless of the outcomes of the clinical trial, within 18 months of: 

  • Trial completion (defined by global LPLV) for all products marketed by UCB 
  • First marketing authorization for an investigational product in either EU or US
  • Decision to discontinue or out-license an investigational product development.

 

[1] In-scope RWE studies are defined as studies (PDC or SDU studies) that are imposed post-authorization safety studies (PASS), imposed post-authorization effectiveness studies (PAES), Category 3 PASS and studies with country-specific requirements for registration and/or posting.